

Report from Barry Greensmith

President PWS Association of Australia
NSW Delegate to PWSAA

November 2006

I met with the PBAC to find out about why the GH submission from Pfizer was rejected and this is a summary of the response.

The main problem was that PABC claimed the submission contained out of date data and that the costing was probably too high.

The PBAC asked Pfizer to make another submission with more recent data and a revised costing. Helping Pfizer with the new submission will be the head of our professional advisory board, Prof Peter Davis along with Dr. Patricia Crock Vice President of APEG. These two very well known professional have all the required data that Pfizer needs and with their connection around the world, a more current and correct case should be made.

The PBAC have asked the PWS Association of Australia for input in the way of an impact statement from all parents on how Prader-Willi Syndrome affects their life. I will have details of the requirements of this impact statement shortly.

The Chair of the PBAC has said that due to Government regulations their hands are tied, but with the right submission it will be passed. The time factor is around 6 months for the next Submission and the CEO of Pfizer at the time suggested they look at GH for adults.